Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Anti-MERS-COV Convalescent Plasma Therapy

NCT02190799 is registered in ClinicalTrials.gov with King Abdullah International Medical Research Center as lead sponsor.

NCT NCT02190799
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02190799 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Anti-MERS-COV Convalescent Plasma Therapy
Lead sponsor
King Abdullah International Medical Research Center
Phase
Phase 2
Overall status
Withdrawn
Start date
May 31, 2014
Completion date
November 30, 2016
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

respiratory distress syndrome (& [hyaline membrane disease])